Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + tislelizumab + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy, known as the GPLET regimen, is a four-drug protocol being evaluated for the treatment of advanced, unresectable, or metastatic cholangiocarcinoma. It consists of lenvatinib (a multi-kinase inhibitor targeting VEGF and FGF receptors), tislelizumab (a humanized IgG4 monoclonal antibody against PD-1), and the chemotherapy doublet gemcitabine and cisplatin. The regimen aims to combine the anti-angiogenic and immunomodulatory effects of lenvatinib with the immune checkpoint blockade of tislelizumab and the cytotoxic effects of standard-of-care chemotherapy. This synergistic approach is intended to overcome the immunosuppressive tumor microenvironment and improve clinical outcomes in biliary tract cancers. The regimen is currently being evaluated in a Phase 3 randomized, double-blind clinical trial (NCT05532059) sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University.
- Other names
- lenvatinib + tislelizumab + gemcitabine + cisplatin-Second Affiliated Hospital, School of Medicine, Zhejiang University-cholangiocarcinomaGPLET regimenLenvatinib, Tislelizumab, Gemcitabine and Cisplatin
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)RNR (Ribonucleotide reductase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on lenvatinib + tislelizumab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + tislelizumab + gemcitabine + cisplatin.